Alantra has advised Eurotech, a multinational company specialising in edge computers and Internet of Things solutions, on a €17.5 million capital increase through a rights issue. The Italian firm, listed on Euronext STAR Milan, achieved 100% subscription with 20,996,430 new ordinary shares issued. The transaction was executed under authority granted by Eurotech's extraordinary shareholders' meeting in October 2024. Alantra served as financial adviser and global coordinator, supporting the offer structuring and institutional placement process. The successful fundraising reflects strong market confidence in Eurotech's Industrial Plan 2026–2030. The deal strengthens Alantra's equity capital markets track record in Italy, following recent mandates including capital increases for Izertis, Clínica Baviera, Expert.AI and Otofarma.

Alantra has closed a €155 million healthcare continuation fund to scale Health in Code, a clinical genomics platform. The oversubscribed vehicle was led by Hayfin Capital Management, with participation from BNP Paribas AM and Altamar CAM, providing liquidity to existing limited partners at three times invested capital. The transaction introduces Mérieux Equity Partners as a 20% minority shareholder through its buyout fund. Health in Code, formed in 2020 through multiple combinations, operates in over 30 countries, focusing on cardiology, oncology, neurology and rare diseases. Under Alantra's ownership, revenues have more than doubled from €24 million to over €50 million. The company targets €100 million in revenues within five years, with approximately 25% of the new capital earmarked for acquisitions across European markets.